摘要
目的研究沙格列汀治疗初发型2型糖尿病疗效以及安全性分析。方法选取2型糖尿病患者47例,随机分成试验组24例,对照组23例,试验组采用沙格列汀5 mg日一次治疗,对照组采用安慰剂。观察两组患者的空腹血糖、餐后血糖、糖化血红蛋白、BMI、肝功能、肾功能。结果两组患者肝功能、肾功能均无异常。试验组治疗前后比较空腹血糖、餐后血糖、糖化血红蛋白明显降低差异有统计学意义(P<0.05),BMI值降低差异有统计学意义(P<0.05)对照组治疗前后各指标无明显变化(P>0.05)。结论沙格列汀治疗初发2型糖尿病效果显著,且安全,值得在临床推广。
Objective To evaluate the efficacy and safety of saxagliptin monotherapy on those Type 2 Diabetic. Methods Select 47 Patients who newly diagnosed or never use oral medicines or Insulin for therapy before. Divided them into Observation group（23 cases） and control group（24 cases）, and control group given saxagliptin once daily, and the observation group were given the same quantity of placebo. Fasting plasma glucose（FPG）, postprandial 2 hours plasma glucose（2hPG）, glycosylated haemoglobin（HbA^c） and body mass index（BMI） were measured and compared after the treatment. Results After the treatment the control group FPG, 2hPG, HbA1c, BMI were better than the befor（P〈0.05）.Observation group had none changed（P〉0.05）. Conclusion Saxagliptin is effective for new type 2 diabetes, worth popularizing in clinical.
出处
《中国医药指南》
2016年第15期9-9,12,共2页
Guide of China Medicine
